Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus, Letrozole, and Trastuzumab in HR+/HER2+ Advanced Cancer
NCT02152943Phase 1Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jul 2014
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of everolimus in breast cancer and solid tumor, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Maximum Tolerated Dose at 21 days and Clinical Benefit Rate up to 4 years. Started Jul 2014; status: completed.
02
Drugs
everolimus
03
Conditions
breast cancersolid tumor
Beyond the preview
Go deeper on NCT02152943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02152943.